Company Profile

With facilities in Baltimore, Maryland and Tarrytown, New York, Profectus BioSciences, Inc. (“Profectus”) is an innovative clinical-stage vaccine company devoted to preventing and treating viral diseases and malaria through the application of its proprietary pDNA and rVSV platform. The company’s name, Profectus, when translated from its Latin roots, means “to advance or improve,” thus capturing the company’s approach to advance products that improve the health of patients suffering from viral diseases and malaria. The company’s vaccine targets include HCV, HPV, HSV, HIV, and malaria. The experienced development team are working on two proprietary platform technologies in-licensed from Wyeth Vaccines (now Pfizer, Inc.). Profectus BioSciences itself is a spinout from the Institute of Human Virology formed to commercialize research spearheaded by Dr. Robert C. Gallo, the famed AIDS co-discoverer who oversees the institute, Profectus is focused on harnessing the immune system to treat and prevent viral diseases and cancers through the delivery of proprietary prime/boost vaccines and small molecules and is developing the next generation of vaccines for high value unaddressed targets in biodefense, infectious, and emerging diseases.